Kremer Hovinga, Johanna A.
Coppo, Paul
Lämmle, Bernhard
Moake, Joel L.
Miyata, Toshiyuki
Vanhoorelbeke, Karen
Article History
First Online: 6 April 2017
Competing interests
: J.A.K.H. serves on the advisory boards of Ablynx for the development of caplacizumab, and Baxalta for the development of recombinant ADAMTS13. Outside the present work, she has received project funding from Baxalta, Bayer, CSL Behring and Novo Nordisk. The hereditary TTP registry (ExternalRef removed,ExternalRef removedidentifier: NCT01257269) is supported by an investigator-initiated research grant from Baxalta. In addition, she receives research funding from the Swiss National Science Foundation (grant 310030–160269), the International Society on Thrombosis and Haemostasis (ISTH) 2007 Presidential Fund and the Answering T.T.P. Foundation. P.C. is a member of the advisory boards of Ablynx for the development of caplacizumab, Alexion for the development of eculizumab and Octapharma for the development of Octaplas. He has received funds from Ablynx, Alexion, Octapharma and Roche. The French Reference Center for Thrombotic Microangiopathies (ExternalRef removed) is in part supported by the French Ministry of Health (Plan National Maladies Rares, Direction Générale de l’Offre de Soin) and the Programme Hospitalier de Recherche Clinique (PHRC 2012 P120118,ExternalRef removedidentifier: NCT02134171). B.L. serves on the advisory board of Ablynx for the development of caplacizumab. He was chairman of the Data Safety Monitoring Board of Baxalta's BAX930 (recombinant ADAMTS13) study in patients with Upshaw–Schulman syndrome. He has received congress and travel support from Alexion, Baxalta and Siemens, and a lecture fee from Siemens. He holds a patent on ADAMTS13. He is supported by the Bundesministerium für Bildung und Forschung (BMBF), Germany. J.L.M. receives research funding from the Mary R. Gibson Foundation and the Mabel and Everett Hinkson Memorial Fund. T.M. reports personal fees from Bayer, Daiich-Sankyo and Alexion, outside the submitted work and is a member of Alexion's atypical haemolytic uraemic syndrome advisory board. He has a patent for Specific substrate and activity measurement method for von Willebrand factor-cleaving protease, Japan Patent Number 3,944,586 issued, and a patent for Substrate polypeptides for von Willebrand factor-cleaving protease ADAMTS13, US Patent Number 7,718,763 issued. K.V. is a member of the advisory board of Ablynx for the development of caplacizumab. She receives research funding from the European Union Framework Program for Research and Innovation (Horizon2020 Marie Sklodowska Curie Innovative Training Network PROFILE grant), the Answering T.T.P Foundation, the Research Foundation Flanders and the KU Leuven Research Foundation.